Key result
Discharge treatment with aspirin plus dipyridamole was associated with a significantly lower 12-month all-cause mortality compared to aspirin only (HR 0.52) in patients with acute ischaemic stroke.
Why the study?
Does aspirin plus dipyridamole reduce mortality and stroke severity compared to aspirin only in patients with acute ischaemic stroke?
Cohort (n=662)
No
Does aspirin plus dipyridamole reduce mortality and stroke severity compared to aspirin only in patients with acute ischaemic stroke?
Answers are grounded in this paper and cite their sources.
Treatment with aspirin plus dipyridamole at discharge after acute ischaemic stroke is associated with lower 12-month all-cause mortality compared to aspirin alone, though it does not reduce acute stroke severity.
BACKGROUND: Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs. The aim of the present study was to evaluate the effect of this drug combination on acute and long-term prognosis of ischaemic stroke. METHODS: Patients without atrial fibrillation admitted to the stroke unit with acute ischaemic stroke (n = 554) or TIA (n = 108) were studied during acute hospital care and up to 12 months after discharge from hospital. RESULTS: Prior to acute stroke 62 patients were treated with A + D while 247 patients were treated with A only. No beneficial effects of the combination A + D compared to A only were noted on stroke severity and/or acute in-hospital mortality. However, survival analysis by Cox-proportional hazard model demonstrated lower 12-months all-cause mortality in patients discharged with A + D (n = 275) compared with patients on A only (HR, 0.52; CI, 0.32-0.86; p = 0.011; n = 262) after adjusting for age, baseline NIHSS, previous stroke, previous myocardial infarction and type 2 diabetes. We also noted a tendency towards lower all-cause mortality at 3 months with use of A + D, but this was not statistically significant (p = 0.12). CONCLUSIONS: Pre-stroke treatment with a combination of low-dose A + D does not reduce the severity of acute stroke, nor does it reduce the acute in-hospital mortality. However, treatment with A + D at discharge from hospital is seemingly associated with lower long-term mortality compared with A only, contrary to the results from previous randomised studies. However, our results must be interpreted with extreme caution considering the non-randomised study design.
No takes yet. Share an insight, caveat, or question.
Arnarsdottir et al. (2012) conducted a cohort in Acute ischaemic stroke or TIA (n=662). Aspirin plus dipyridamole vs. Aspirin only was evaluated on 12-month all-cause mortality (HR 0.52, 95% CI 0.32-0.86, p=0.011). Discharge treatment with aspirin plus dipyridamole was associated with a significantly lower 12-month all-cause mortality compared to aspirin only (HR 0.52) in patients with acute ischaemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: